PMID- 29938620
OWN - NLM
STAT- MEDLINE
DCOM- 20200608
LR  - 20220410
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 17
IP  - 6
DP  - 2019
TI  - Diabetes in Menopause: Risks and Management.
PG  - 556-563
LID - 10.2174/1570161116666180625124405 [doi]
AB  - The aim of this review is to present, critically appraise and qualitatively 
      synthesize current evidence on the risk of type 2 diabetes mellitus (T2DM) 
      development during menopause, the management of climacteric symptoms in women 
      with T2DM and the management of T2DM in postmenopausal women. Menopause 
      represents the end of reproductive life in women, as a result of ovarian aging. 
      It is characterized by substantial decrease in the endogenous oestrogen 
      concentrations and it is accompanied by alterations in body weight, adipose 
      tissue distribution and energy expenditure, as well as insulin secretion, insulin 
      sensitivity and activity that can predispose to the development of T2DM, 
      independently of, and additively to, aging. Many women in midlife experience 
      climacteric symptoms, including hot flushes and night sweats, resulting in an 
      indication to receive Hormone Replacement Treatment (HRT). HRT has a favourable 
      effect on glucose homeostasis both in women without and with T2DM. The latter was 
      considered in the past as a cardiovascular disease (CVD) equivalent, which would 
      suggest that women with the disease should not receive HRT. However, nowadays 
      evidence exists to support an individualized approach of women based on their CVD 
      risk, as some women with T2DM may be excellent candidates for HRT. Regarding T2DM 
      management for women in menopause, lifestyle intervention, including diet and 
      exercise, constitutes its cornerstone. However, most of these women will 
      eventually require pharmacologic therapy. The most suitable agents should be 
      selected according to their metabolic, cardiovascular and bone effects, taking 
      into consideration the specific characteristics and comorbidities of each 
      postmenopausal woman.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Paschou, Stavroula A
AU  - Paschou SA
AD  - Division of Endocrinology and Diabetes, "Aghia Sophia" Hospital, Medical School, 
      National and Kapodistrian University of Athens, Athens, Greece.
FAU - Anagnostis, Panagiotis
AU  - Anagnostis P
AD  - Unit of Reproductive Endocrinology, First Department of Obstetrics and 
      Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, 
      Greece.
FAU - Pavlou, Dimitra I
AU  - Pavlou DI
AD  - Forth Department of Internal Medicine, Hippokration Hospital, Medical School, 
      Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Vryonidou, Andromachi
AU  - Vryonidou A
AD  - Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, 
      Greece.
FAU - Goulis, Dimitrios G
AU  - Goulis DG
AD  - Unit of Reproductive Endocrinology, First Department of Obstetrics and 
      Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, 
      Greece.
FAU - Lambrinoudaki, Irene
AU  - Lambrinoudaki I
AD  - Division of Endocrinology and Diabetes, Second Department of Obstetrics and 
      Gynecology, Medical School, National and Kapodistrian University of Athens, 
      Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/epidemiology/metabolism/physiopathology/*therapy
MH  - Diet, Healthy
MH  - *Estrogen Replacement Therapy/adverse effects
MH  - Exercise
MH  - Female
MH  - *Healthy Lifestyle
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Menopause/*drug effects/metabolism
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - cardiovascular disease
OT  - epidemiology
OT  - hormone replacement treatment
OT  - menopause
OT  - women health.
EDAT- 2018/06/26 06:00
MHDA- 2020/06/09 06:00
CRDT- 2018/06/26 06:00
PHST- 2018/03/31 00:00 [received]
PHST- 2018/06/05 00:00 [revised]
PHST- 2018/06/16 00:00 [accepted]
PHST- 2018/06/26 06:00 [pubmed]
PHST- 2020/06/09 06:00 [medline]
PHST- 2018/06/26 06:00 [entrez]
AID - CVP-EPUB-91248 [pii]
AID - 10.2174/1570161116666180625124405 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2019;17(6):556-563. doi: 10.2174/1570161116666180625124405.